Abstract: SA-PO0669
Systemic Corticosteroids Combined with Targeted-Release Budesonide in Primary IgAN: A Single-Center Real-World Study
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Gong, Shaomin, Zhongshan Hospital, Fudan University, Shanghai, China
- Ning, Yichun, Zhongshan Hospital, Fudan University, Shanghai, China
- Shen, Ziyan, Zhongshan Hospital, Fudan University, Shanghai, China
- Jin, Shi, Zhongshan Hospital, Fudan University, Shanghai, China
- Liu, Hong, Zhongshan Hospital, Fudan University, Shanghai, China
- Shi, Yiqin, Zhongshan Hospital, Fudan University, Shanghai, China
- Ding, Xiaoqiang, Zhongshan Hospital, Fudan University, Shanghai, China
Background
Systemic corticosteroids and targeted-release budesonide (Nefecon) are both effective in treating IgA nephropathy (IgAN). The former has the advantage of rapid onset, but long-term use increases related adverse events, while the latter is released in the terminal ileum inhibiting the production of pathogenic antibodies with few long-term adverse events. Thus, we hypothesized that the combination of the two drugs can act together through different mechanisms and different time phases to improve proteinuria more rapidly and effectively without increasing adverse events. This study aimed to evaluate the efficacy of systemic corticosteroids combined with Nefecon in patients with primary IgAN.
Methods
We retrospectively included patients with primary IgAN who received systemic corticosteroids combined with Nefecon at Single center from January 2025 to June 2025. Baseline characteristics and follow-up data after 16 weeks of treatment were collected and analyzed.
Results
A total of 59 patients aged 41.75 ± 12.16 years were analyzed, including 35 male (59.32%). Baseline 24-hour proteinuria (UTP) was 2.50 ± 2.40 g and baseline eGFR was 52.17 ± 30.26 ml/min/1.73m^2 (Table 1). Patients received systemic corticosteroids were described in Table 2. After 8 weeks, UTP decreased by 30.62% from baseline (P=0.003), and by 53.92% at 16 weeks (P<0.001), which suggested that combination therapy exerts a faster onset of action compared with Nefecon monotherapy reported in the NefIgArd trial. The eGFR increased by 4.47% from baseline at week 8 (P=0.199) and by 8.06% at week 16 (P=0.038). No serious infections occurred during the period, and 1 patient discontinued due to poor efficacy.
Conclusion
Systemic corticosteroids combined with Nefecon in primary IgAN showed a significant and sustained ability to improve proteinuria and renal function as early as week 8 without severe adverse events, suggesting a promising clinical treatment option.